Acupuncture for Chronic Lymphedema

Phase 2

Completed

• Conditions: Breast Cancer With Chronic Lymphedema
• Interventions: Procedure: Wait-list; Procedure: Acupuncture

• Registration Number: NCT01706081
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

This study is being done because women have arm swelling for more than 6 months despite wrapping and other treatments. This swelling is called lymphedema. It is the back up of lymph system fluid that causes swelling in the arm. The swelling can just happen, but more commonly it is caused when lymph nodes are removed during cancer surgery. It can develop right after breast cancer treatment or weeks, months or even years later. In our preliminary research, the investigators found that more than 1/3 of the 33 patients showed at least a 30% reduction in lymphedema following acupuncture treatment and there were no serious adverse events during the treatment or 6 month followup.

This study will include a larger group of patients. Patients will be assigned to one of two groups, and results of the groups will be compared to see if acupuncture can reduce lymphedema and whether the effect lasts after acupuncture treatment is completed.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-10
• Study First Submitted: 2012-10-10
• Study First Submitted QC: 2012-10-12
• Study First Posted: 2012-10-15
• Status Verified: 2018-04
• Primary Completion: 2018-04-11
• Study Completion: 2018-04-11
• Results First Submitted: 2018-05-21
• Results First Submitted QC: 2019-07-24
• Last Update Submitted: 2019-07-24
• Results First Posted: 2019-08-29
• Last Update Posted: 2019-08-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 82

Inclusion Criteria

• Women age 18 or older
• Lymphedema in an arm as a result of surgery, chemotherapy, and/or radiation therapy for breast cancer per breast surgeon or medical oncologist
• Patients must have received a clinical diagnosis of lymphedema for at least 6 months and no more than 5 years. This timeframe allows ample time for any surgically related non lymphedema swelling to subside by 6 months post-surgery, while a cap of 5 years will capture the broadest range of cases, and has been used as a timeframe in several studies including our pilot study.
• The affected arm must be >2cm larger than the unaffected arm. Differences of 2 cm or more between the affected and unaffected arm are considered by experts to be clinically significant. Each affected arm will be measured in two areas: upper arm and forearm.

The larger of the two measures-upper arm or forearm- will be used for analysis.

• Classified as International Society of Lymphology (ISL) stage II or higher as determined by an MSKCC Certified Lymphedema Therapist (CLT).

Read More

Exclusion Criteria

• Bilateral lymphedema
• Previous acupuncture treatment for lymphedema
• Concurrent diuretic use
• History of primary (congenital) lymphedema
• Pregnant or planning to become pregnant during the course of the study
• Has an implanted electronically charged medical device

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Wait-list	Wait-list	Patients in the wait-list control group will cross over and receive acupuncture twice weekly for 6 consecutive weeks.
Acupuncture	Acupuncture	Patients in the acupuncture group will receive acupuncture treatment twice weekly for six consecutive weeks.

Primary Outcome Measures

Name	Time	Method
Lymphedema as Measured at Baseline and at 6 Weeks	6 weeks	Changes in lymphedema between groups, as measured by mean arm circumference assessed at baseline and after 6 weeks from baseline.

Secondary Outcome Measures

Name	Time	Method
Measurements for Bioimpedance for Treatment Arms at Baseline and 6 Weeks	6 weeks	Bioimpedance measured using Impedimed L-Dex U400, which measures the rate of electrical current transmission through tissues and estimate fluid content in a lymphedematous limb compared with the normal limb.
Number of Participants Evaluated for Adverse Events	1. 5 years

Trial Locations

Locations (1)

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States